Search

Author/Creator Dijkstra, G

41. P394 Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel Disease. (27th May 2021)

Authors:
Sorokina Alexdóttir, M; Bourgonje, A R; Asser Karsdal, M; Bay-Jensen, A C; Faber, K N; Loveikyte, R; van Dullemen, H M; Visschedijk, M C; Festen, E A M; Weersma, R K; Dijkstra, G; Mortensen, J H
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S403
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

42. P456 Drug survival of thiopurine–allopurinol combination therapy in a real-life population-based cohort. (16th January 2018)

Authors:
Kreijne, J E; de Veer, R C; de Boer, N K; Bouma, G; Dijkstra, G; West, R L; van Bodegraven, A A; de Jong, D J; van der Woude, C J; de Vries, A C
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S335
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

43. P459 High inadequate surveillance rates in colitis-associated advanced neoplasia: a multicenter retrospective cohort study. (21st January 2022)

Authors:
Te Groen, M; Derks, M E; Peters, C P; Dijkstra, G; De Vries, A C; Römkens, T E; Horjus, C S; De Boer, N K; De Jong, M E; Nagtegaal, I D; Derikx, L A; Hoentjen, F
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i435
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

44. P460 Biomarkers reflecting extracellular matrix turnover and inflammation can be used to monitor disease activity and treatment response in patients with Crohn's disease undergoing infliximab induction therapy. (27th May 2021)

Authors:
Sorokina Alexdóttir, M; Bourgonje, A R; Asser Karsdal, M; Bay-Jensen, A C; Faber, K N; Loveikyte, R; van Dullemen, H M; Visschedijk, M C; Festen, E A M; Weersma, R K; Dijkstra, G; Mortensen, J H
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S453
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

45. P464 Switching from the originator infliximab to biosimilar CT-P13 did not change the quality of life and clinical efficacy for IBD patients in stable remission in daily clinical practice (interim analysis). (16th January 2018)

Authors:
Pierik, M J; van der Meulen-de Jong, A E; Bloemsaat-Minekus, J P J; van Megen, Y J B; Dijkstra, G
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S339
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

46. P503 Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC case series, a nationwide prospective observational cohort study. (25th January 2019)

Authors:
Biemans, V; van der Woude, J; Dijkstra, G; van der Meulen-de Jong, A; Oldenburg, B; de Boer, N; Löwenberg, M; Srivastava, N; Jansen, J; West, R; de Vries, A; Haans, J; Pierik, M; Hoentjen, F
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S363
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

47. P509 Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn's disease. (21st January 2022)

Authors:
Sorokina Alexdóttir, M; Bourgonje, A R; Karsdal, M A; Bay-Jensen, A C; Pehrsson, M; Loveikyte, R; van Dullemen, H M; Visschedijk, M C; Festen, E A M; Weersma, R K; Faber, K N; Dijkstra, G; Joachim H, M
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i468
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

48. P577 Mucosal eosinophil abundance in non-inflamed colonic tissue predict response to vedolizumab induction therapy in inflammatory bowel disease. (21st January 2022)

Authors:
Gabriëls, R Y; Bourgonje, A R; von Martels, J; Blokzijl, T; Weersma, R; Galinsky, K; Julius, J; Faber, K N; Kats-Ugurlu, G; Dijkstra, G
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i517
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

49. P587 Drug survival of vedolizumab-treated inflammatory bowel disease patients in a nationwide observational cohort study: ICC case series. (16th January 2018)

Authors:
Biemans, V; van der Woude, C; Dijkstra, G; van der Meulen - de Jong, A; Oldenburg, B; de Boer, N; Ponsioen, C; de Vries, A; Haans, J; Pierik, M; Hoentjen, F
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S404
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

50. P606 Use of TNF-α-antagonists and systemic steroids is associated with attenuated immunogenicity against SARS-CoV-2 in fully vaccinated patients with Inflammatory Bowel Disease. (21st January 2022)

Authors:
Otten, A T; Bourgonje, A R; Horinga, P P; van der Meulen, H H; van Leer-Buter, C C; Dijkstra, G; Visschedijk, M C
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i538
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗